Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Myriad Genetics (NASDAQ: MYGN) announced that Sam Raha, president and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, 2026 at 5:15 pm PT (8:15 pm ET). The presentation will be available via a live webcast and an archived replay at the company’s investor website: investor.myriad.com.

Key Figures

Conference edition 44th Annual J.P. Morgan Healthcare Conference

Presentation date Jan. 14, 2026 Scheduled conference presentation in San Francisco

Presentation time PT 5:15 pm PT Scheduled time for J.P. Morgan presentation

Presentation time ET 8:15 pm ET Simulcast time for J.P. Morgan presentation

Market Reality Check

$6.52 Last Close

Volume Volume 705,847 vs 20-day average 894,627, about in-line at 0.79x typical activity. normal

Technical Shares at $6.14 are trading below the 200-day MA of $6.51, after a large slide from the $15.47 52-week high.

Peers on Argus

Peers show mixed moves: FLGT (-2.59%), CSTL (-1.23%), PSNL (-3.33%), NEO (-1.01%), while CDNA is up 1.59%. Another peer, NEO, also issued a J.P. Morgan conference participation release, suggesting conference-related but company-specific positioning rather than a broad sector move.

Common Catalyst Participation in the 44th Annual J.P. Morgan Healthcare Conference appears as a shared theme for at least one peer (NEO), indicating investor updates via conference presentations across the diagnostics space.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Dec 09	Conference research data	Positive	+4.0%	Presentation of 8 SABCS abstracts including MRD and expanded MyRisk data.
Nov 25	Product collaboration	Positive	-3.9%	Launch of integrated AI and genetic breast health risk platform with partners.
Nov 11	Investor conferences	Neutral	+3.1%	Planned participation in Wolfe and Piper Sandler healthcare investor conferences.
Nov 10	Product expansion	Positive	+2.9%	Added 15 genes to MyRisk, expanding to 63 guideline-aligned hereditary cancer genes.
Nov 06	Conference research data	Positive	-3.8%	Planned 11 new studies at NSGC conference on oncology and reproductive testing.

Pattern Detected

Recent company news often centers on conferences and product/clinical updates, with a mix of aligned and divergent price reactions, indicating that seemingly positive announcements have not consistently driven upside.

Recent Company History

Over the last few months, Myriad Genetics has emphasized scientific visibility and product expansion. It highlighted 11 genetic testing studies at the NSGC 2025 conference and later expanded its MyRisk panel to 63 genes across more than 11 cancer types. The company then announced participation in late-2025 investor conferences and, in December, slated 8 abstracts for SABCS, showcasing its MRD and hereditary cancer capabilities. Today’s J.P. Morgan appearance continues this pattern of using major forums to communicate strategy and data.

Market Pulse Summary

This announcement highlights Myriad’s plan to communicate its story at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 14, offering management a forum to discuss strategy, operations, and pipeline. Recent history shows a steady cadence of conference participation and product updates, alongside ongoing losses and leadership changes in SEC filings. Investors may watch for any commentary on revenue trends, debt obligations, and progress across hereditary cancer, prenatal, and MRD testing franchises.

Key Terms

molecular diagnostic testing medical

"Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine"

Molecular diagnostic testing uses tools that read the genetic material or specific molecules from a tissue, blood, or swab sample to detect disease, identify pathogens, or predict how a patient will respond to treatment. Think of it like a highly detailed fingerprint check for the biology of an illness. Investors care because these tests drive sales, regulatory scrutiny, and reimbursement decisions, so accuracy, adoption, and approval directly affect a company’s revenue and growth prospects.

precision medicine medical

"a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha"

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

webcast technical

"The presentation will be available through a live webcast and archived at investor.myriad.com."

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

SALT LAKE CITY, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Sam Raha, president and CEO, will present at the 44^th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 14, at 5:15 pm PT (8:15 pm ET).

The presentation will be available through a live webcast and archived at investor.myriad.com. 

About Myriad Genetics  
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com. 

Investor Contact  
Matt Scalo  
(801) 584-3532  
IR@myriad.com  

Media Contact  
Kate Schraml 
(224) 875-4493 
PR@myriad.com 

FAQ

When will Myriad Genetics (MYGN) present at the J.P. Morgan Healthcare Conference?

Myriad Genetics will present on Wednesday, Jan. 14, 2026 at 5:15 pm PT (8:15 pm ET).

Who from Myriad Genetics will present at the Jan. 14, 2026 conference?

Sam Raha, president and CEO of Myriad Genetics, will deliver the presentation.

How can investors watch Myriad Genetics (MYGN) presentation on Jan. 14, 2026?

The presentation will be available via a live webcast and an archived replay at investor.myriad.com.

What time is Myriad Genetics (MYGN) presenting in Eastern Time?

The presentation is scheduled for 8:15 pm ET on Jan. 14, 2026.

Will a replay of the Myriad Genetics presentation be available after Jan. 14, 2026?

Yes. An archived replay will be posted at investor.myriad.com following the live webcast.